ArticleAlimentary pharmacology & therapeutics2017

The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.

E H Elbasha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.